OKYO Pharma Bullish Thesis
OKYO Pharma's presentation highlights their key drug candidate, OK-101, developed to treat Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).
Okyo Pharma Ltd (OKYO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 41,200 | $82,400 | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 15,355 | $30,710 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.50 | 16,670 | $25,005.00 | 16,670 | 2023-09-15 | Filing | |
| $0.08 | 5,800,000 | $440,800.00 | 548,981,215 | 2022-05-19 | Filing | |
| $4.00 | 12,500 | $50,000.00 | 12,500 | 2022-05-19 | Filing | |
| $4.00 | 37,500 | $150,000.00 | 62,500 | 2022-05-19 | Filing | |
| $3.87 | 25,000 | $96,750.00 | 25,000 | 2022-05-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,422,048 | $4,844,096 | 3.03% | |
| 2. | 57,158 | $114,316 | 0% | |
| 3. | 12,812 | $25,624 | 0% | |
| 4. | 12,090 | $24,180 | 0% | |
| 5. | 10,000 | $20,300 | 0% |
News See All
